Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo.

ABSTRACT:

Introduction

The randomized IronIC trial evaluated the effect of intravenous ferric derisomaltose on physical capacity in iron-deficient, maintenance heart transplant (HTx) recipients. Iron deficiency was defined as in heart failure with high cut-points for ferritin to compensate for inflammation. However, intravenous iron did not improve physical capacity except in patients with ferritin <30 μg/L. We aimed to explore determinants of iron status in the 102 IronIC participants to better define iron deficiency in the HTx population.

Methods

We assessed key governors of iron homeostasis, such as hepcidin, soluble transferrin receptor (sTfR), and interleukin-6 (IL-6). We also measured growth factors and inflammatory markers with relevance for iron metabolism. The results were co

SUBMITTER: Brautaset Englund KV 

PROVIDER: S-EPMC9541327 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature